Axsome Therapeutics (AXSM) Total Debt (2015 - 2026)

Axsome Therapeutics has reported Total Debt for 12 years, with the latest figure at $129.0 million in Q1 2026.

• Quarterly Total Debt fell 32.1% year-over-year to $129.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $129.0 million (down 32.1% YoY) and the FY2025 annual result came in at $127.8 million, down 29.3% from the prior year.
• Total Debt advanced to $129.0 million in Q1 2026 per AXSM's latest filing, from $127.8 million in the prior quarter.
• Over five years, Total Debt peaked at $190.0 million in Q1 2025 and troughed at $49.3 million in Q1 2022.
• A 5-year average of $141.0 million and a median of $129.0 million in 2026 frame the typical range for Total Debt.
• The sharpest annual moves came in 2023 and 2024: Total Debt soared 211.51% in 2023, then plunged 52.13% in 2024.
• Over 5 years, Total Debt stood at $100.2 million in 2022, then jumped by 84.18% to $184.5 million in 2023, then declined by 2.04% to $180.7 million in 2024, then fell by 29.3% to $127.8 million in 2025, then gained by 0.97% to $129.0 million in 2026.
• According to Business Quant data, Total Debt over the past three periods registered $129.0 million, $127.8 million, and $127.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.